See the DrugPatentWatch profile for Kymriah
What were Kymriah’s sales figures (and how much did they change over time)?
Kymriah’s revenue and sales performance aren’t provided in the information available here, so I can’t give specific sales numbers or a timeline without more details (for example, which year(s), which geography like the US/EU, or whether you mean global revenue vs. US-only sales).
How are Kymriah sales reported—global revenue or US/region-specific “sales”?
Kymriah (tisagenlecleucel) results in revenue that can show up in different ways depending on the data source:
- Company reported revenues (often global, sometimes with region segmentation).
- Sales reported as product revenue in financial filings (which may reflect billing, timing, and contract structure).
- Analyst or database estimates, which may differ from company figures.
If you tell me the year and region you want, I can align the numbers to the right reporting definition.
Who makes Kymriah and how do sales tie to revenue guidance?
Kymriah is marketed by Novartis. Sales patterns for CAR-T products often tie closely to:
- Patient demand and referral rates.
- Manufacturing slot capacity and lead times.
- Reimbursement and center adoption.
- Ongoing competitive pressures from other CAR-Ts and treatment alternatives.
But specific links to guidance or quarter-by-quarter impacts require the missing sales dataset or a reference to financial reports you want used.
How do Kymriah sales compare with other CAR-T therapies?
A direct comparison needs sales figures for Kymriah and the comparator products (such as Yescarta, Tecartus, Breyanzi, etc.). Without those numbers, any comparison would be speculative.
If you want, I can pull the exact sales—what details should you specify?
Reply with:
1) Which year(s) (e.g., 2023, 2024, last quarter)
2) Which geography (global, US, Europe, specific country)
3) Whether you want product sales/revenue or prescriptions/volume
Once you confirm, I can provide the precise Kymriah sales figures in the format you prefer.